The COVID-19 pandemic certainly disrupted the healthcare industry... from how we met with our doctors (if we went at all) to how we got our medications to how successfully new products launched. A new report from IQVIA* demonstrates what has happened and gives us a peek into, perhaps, where the future is going.
While down from the peak a year ago, telehealth visits are still up 1500%, as compared to pre-pandemic levels. Telehealth represented roughly 1% of visits prior to the pandemic, increasing to almost 30% in April 2020 and now has maintained 9% to 11% since summer 2020.
With fewer patients in the office, digital plays an increasing role in providing needed information. We need to find ways to target them across their digital ecosystem to provide relevant, engaging content.
Overall, people are still delaying making doctor’s visits. While office medical claims are rebounding, institutional medical claims are still behind. In fact, in 2020 there were almost 1 billion fewer diagnosis visits than in 2019.
Do we need to increase disease awareness efforts to reinforce the need to return to the doctors’ office to optimally manage health?
It’s estimated this will result in 15 million fewer prescriptions written in the first half of 2021 – down approximately 0.5%
New vs Continuing Prescription Levels Vary By Specialty
YoY Cumulative NBRx/TRx Growth by Selected Specialty Rolling 52-Week YoY Comparison
In FY 2020, there were 63 launches compared to 69 in FY 2019 (NMEs + promoted branded generics).
Of the 49 products approved, only 3 announced a delay due to COVID but were subsequently launched.
Ten months into COVID, launches do appear to be impacted.
Staying on the topic of the FDA, from December 2019 to present, the FDA met their 45-day promotional review period almost 100% of the time (a sharp increase from 2019).
There was only a small portion of people who switched from retail to mail-order perscription, and many are switching back to the in-store experience.
The pharmacy is still a primary channel to reach and engage our patients and caregivers.
Retail performance is slowing as COVID vaccines decline;
Mail YoY performance has increased 5.7%
COVID-19 had a huge impact on clinical trials. Many patients enrolled in trials may have been vulnerable to infection and traveling to sites could have been detrimental if exposed to COVID-19.
Clinical trials were impacted by:
But we now see an increase to a volume higher than in 2019:
*IQVIA US Pharmaceutical Trends, Issues and Outlook for DSN. June 2021